The Current Lung Cancer Neoantigen Landscape and Implications for Therapy

Ye, Linda; Creaney, Jenette; Redwood, Alec; Robinson, B. W.

doi:10.1016/j.jtho.2021.01.1624

Cited by 27 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36,52,53 Interestingly, these reported cancer types have very diverse immunopathology and hence are likely to mount distinct changes in the immune landscape during infection. [54][55][56] Hematological malignancies and/or blood cancer are liquid (leukemias) or are localized to sites of development and/or primary ie, bone marrow or secondary lymphoid organs, unlike most solid tumors. [57][58][59] These features make hematological malignancies highly available to interactions with immune cells and respond avidly to on-going systemic inflammatory responses (such as those observed during severe…”

Section: Sars-cov-2 Infection In Cancer Patientsmentioning

confidence: 99%

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Latif

Shukla

Estrada

et al. 2022

Translational Research

View full text Add to dashboard Cite

Section: Sars-cov-2 Infection In Cancer Patientsmentioning

confidence: 99%

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Latif

Shukla

Estrada

et al. 2022

Translational Research

View full text Add to dashboard Cite

“…The presence of neoantigen-reactive T-cells has been assessed across different cancer histologies, such as lung cancer [ 170 , 171 ], bladder cancer [ 172 ], head and neck cancer [ 173 , 174 ], ovarian cancer [ 175 , 176 , 177 , 178 ], pancreatic cancer [ 179 , 180 ] and gastrointestinal epithelial malignancies [ 181 , 182 , 183 , 184 ].…”

Section: Tcr and Cancermentioning

confidence: 99%

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

Mazzotti

Gaimari

Bravaccini

et al. 2022

IJMS

View full text Add to dashboard Cite

The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and biological agents shape the development and behavior of this complex and diffuse system. Many pathological conditions depend on how our immune system responds or does not respond to a pathogen or a disease or on how the regulation of immunity is altered by the disease itself. T-cells are important players in adaptive immunity and, together with B-cells, define specificity and monitor the internal and external signals that our organism perceives through its specific receptors, TCRs and BCRs, respectively. Today, high-throughput sequencing (HTS) applied to the TCR repertoire has opened a window of opportunity to disclose T-cell repertoire development and behavior down to the clonal level. Although TCR repertoire sequencing is easily accessible today, it is important to deeply understand the available technologies for choosing the best fit for the specific experimental needs and questions. Here, we provide an updated overview of TCR repertoire sequencing strategies, providers and applications to infectious diseases and cancer to guide researchers’ choice through the multitude of available options. The possibility of extending the TCR repertoire to HLA characterization will be of pivotal importance in the near future to understand how specific HLA genes shape T-cell responses in different pathological contexts and will add a level of comprehension that was unthinkable just a few years ago.

show abstract

“…Additionally, it is not feasible to determine neoantigen load in daily practice. Tumor mutation burden (TMB), defined as the total number of somatic/acquired mutations per coding area of a tumor genome (Mut/Mb), has failed to consistently predict response to ICIs thus far [ 27 , 28 ].…”

Section: Cancer Vaccines: Taas and Antigen Selectionmentioning

confidence: 99%

Vaccine Therapy in Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as a new standard of care for multiple indications, including non-small cell lung cancer (NSCLC). However, prognosis for patients with lung cancer is still poor. Although immunotherapy is highly effective in some cases, not all patients experience significant or durable responses, and further strategies are needed to improve outcomes. Therapeutic cancer vaccines are designed to exploit the body’s immune system to activate long-lasting memory against tumor cells that ensure tumor regression, with minimal toxicity. A unique feature of cancer vaccines lies in their complementary approach to boost antitumor immunity that could potentially act synergistically with immune checkpoint inhibitors (ICIs). However, single-line immunization against tumor epitopes with vaccine-based therapeutics has been disappointingly unsuccessful, to date, in lung cancer. The high level of success of several recent vaccines against SARS-CoV-2 has highlighted the evolving advances in science and technology in the vaccines field, raising hope that this strategy can be successfully applied to cancer treatments. In this review, we describe the biology behind the cancer vaccines, and discuss current evidence for the different types of therapeutic cancer vaccines in NSCLC, including their mechanisms of action, current clinical development, and future strategies.

show abstract

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy

Cited by 27 publications

References 65 publications

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

Vaccine Therapy in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About